Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Current Assets: 2013-2025

Historic Current Assets for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $354.7 million.

  • Theravance Biopharma's Current Assets rose 204.51% to $354.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $354.7 million, marking a year-over-year increase of 204.51%. This contributed to the annual value of $161.1 million for FY2024, which is 20.61% up from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Current Assets is $354.7 million, which was down 3.17% from $366.3 million recorded in Q2 2025.
  • Theravance Biopharma's Current Assets' 5-year high stood at $511.7 million during Q3 2022, with a 5-year trough of $116.5 million in Q3 2024.
  • Over the past 3 years, Theravance Biopharma's median Current Assets value was $161.1 million (recorded in 2024), while the average stood at $194.6 million.
  • Its Current Assets has fluctuated over the past 5 years, first crashed by 68.40% in 2023, then surged by 207.02% in 2025.
  • Theravance Biopharma's Current Assets (Quarterly) stood at $249.9 million in 2021, then soared by 41.46% to $353.5 million in 2022, then plummeted by 62.22% to $133.5 million in 2023, then rose by 20.61% to $161.1 million in 2024, then soared by 204.51% to $354.7 million in 2025.
  • Its Current Assets stands at $354.7 million for Q3 2025, versus $366.3 million for Q2 2025 and $150.3 million for Q1 2025.